Pooled Baseline Characteristics of Women in Phase III Benralizumab Asthma Exacerbation Studies (SIROCCO and CALIMA)

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.304
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P68 Asthma Symptom Improvements With Benralizumab Are Associated With Improvements in Activity Functions and Quality of Life for Patients With Severe, Uncontrolled Asthma: Results of Pooled Phase Iii Benralizumab Studies

2017English

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients With Severe Eosinophilic Asthma

Advances in Therapy
MedicinePharmacology
2019English

Relationship of Asthma Management, Socioeconomic Status, and Medication Insurance Characteristics to Exacerbation Frequency in Children With Asthma

Annals of Allergy, Asthma and Immunology
Respiratory MedicinePulmonaryAllergyImmunology
2011English

Circulating microRNAs and Prediction of Asthma Exacerbation in Childhood Asthma

Respiratory Research
PulmonaryRespiratory Medicine
2018English

Benralizumab for the Treatment of Severe Eosinophilic Asthma

Prescriber
Pharmacology
2018English

Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients With Asthma

Clinical Pharmacokinetics
Pharmacology
2019English

Phase-Iii-Studien Zu E25 Bei Asthma

Allergo Journal
AllergyImmunology
2000English

Overall and Cardiovascular Safety of Aclidinium Bromide in Patients With COPD: A Pooled Analysis of Six Phase III, Placebo-Controlled, Randomized Studies

Chronic Obstructive Pulmonary Diseases
PulmonaryRespiratory Medicine
2016English

The Clinical Profile of Benralizumab in the Management of Severe Eosinophilic Asthma

Therapeutic Advances in Respiratory Disease
PulmonaryRespiratory MedicinePharmacology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy